A

Alcon

Eye care products and vision solutions

Principal Software Engineer - Software Engineering

Full-TimeUpdated on 10/23/2026Deadline 11/19/26
No salary listed
Expert
Bachelor's, Master's
Bengaluru, Karnataka, India
In PersonWork hours: 1 PM to 10 PM IST.
Software Engineering

About the job

Requirements
  • A Bachelor's or Master's degree and at least 7 years of total experience are required.
  • Experience with C# and the .NET Framework, .NET Core, or .NET 6, 7, or 8 is required.
  • Experience with Python, SQL, and JavaScript is required.
  • Experience with .NET Core, ASP.NET Core, Web API, RESTful services, MVC, Entity Framework or other ORM tools, microservices using .NET, OpenAPI or Swagger, and NuGet is required.
  • Hands-on experience with UI and API automation frameworks, including Selenium and Ranorex, is required.
  • Experience with REST-based API testing frameworks, designing scalable enterprise automation frameworks, test strategy, regression automation, and CI-integrated automation is required.
  • Experience integrating automation into CI/CD pipelines and scripting with Python and/or C# is required.
  • Knowledge of enterprise solution architecture, microservices architecture, Domain-Driven Design, distributed systems design, event-driven architecture, enterprise integration patterns, API design and governance, security architecture, high availability and resiliency design, scalability and performance engineering, and enterprise application modernization is required.
  • Experience with AWS Cloud Services, Kubernetes, Docker, CI/CD pipelines, Jenkins, GitHub Actions, infrastructure automation, DevSecOps practices, containerization, and orchestration is required.
  • Experience with Datadog, Zipkin, distributed tracing, application monitoring, log aggregation and analysis, performance tuning, reliability engineering, production support, operational excellence, bottleneck analysis and optimization, and production-readiness validation is required.
  • Hands-on expertise with JMeter and NeoLoad is required, including designing workload models, executing performance tests, analyzing bottlenecks, and end-to-end load testing, stress testing, and capacity planning.
  • Experience with relational database management systems, data modeling and database design, query optimization and performance tuning, data migration and integrity strategies, transaction management, and database scalability and reliability is required.
  • Knowledge of generative AI, LangChain, AI agents, retrieval-augmented generation, vector databases, large language model integration and orchestration, intelligent automation solutions, and enterprise knowledge management systems is required.
  • Ability to diagnose, troubleshoot, and resolve complex technical challenges in distributed enterprise environments is required.
  • Expertise in architectural decision-making and technology leadership is required.
  • Ability to translate business requirements into scalable, maintainable, and secure technical solutions is required.
  • Ability to balance strategic architecture responsibilities with hands-on technical execution is required.
  • Experience driving engineering excellence and modernization initiatives is required.
Responsibilities
  • Lead architecture, design, and implementation of scalable, secure, high-performing enterprise applications and cloud-native solutions.
  • Define architecture standards, design principles, and engineering best practices across teams.
  • Partner with Development, QA, Automation, Performance, and DevOps teams to drive quality engineering, automation strategy, and production readiness.
  • Drive modernization and cloud transformation initiatives to ensure scalability, reliability, and operational excellence.
  • Perform architectural assessments and provide scalable, sustainable solutions to complex technical challenges.
  • Lead architecture, design, and production-readiness reviews to ensure adherence to enterprise standards.
  • Own performance engineering by defining workload models, capacity strategies, and executing tests using tools such as JMeter and NeoLoad.
  • Troubleshoot complex production issues across distributed systems and drive root-cause resolution.
  • Collaborate with stakeholders to translate business requirements into scalable and robust solutions.
  • Drive observability, monitoring, and reliability engineering practices to ensure system stability.
  • Mentor engineering teams and influence strategic technology decisions.
  • Evaluate and adopt emerging technologies and automation capabilities to improve delivery efficiency.
Desired Qualifications
  • Experience with Java (JDK 8, 11, 17, or 21) for interoperability and legacy-system understanding.
  • Experience working with Java-based services and APIs.

About the company

A

Alcon

View
cbWebsite

Alcon provides eye care products and vision solutions to improve how people see. It develops and manufactures devices and consumables for eye health, including cataract surgery equipment and intraocular lenses, retinal health therapies, and contact lenses, distributed through eye care professionals, hospitals, and consumers. The products work by supporting eye surgery, protecting and restoring vision, or correcting vision with lens-based options, backed by research and development and a global distribution network. Alcon differentiates itself with a broad, end-to-end portfolio across the eye care continuum, a strong emphasis on research and development, strategic partnerships with healthcare providers, and a commitment to diversity and inclusion. Its goal is to enhance vision and quality of life by delivering reliable, high-quality eye care solutions and advancing the science of eye health.

Company Size

10,001+

Company Stage

IPO

Headquarters

Geneva, Switzerland

Founded

1945

Get referred to Alcon

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Systane PRO PF launched in Canada on September 28, 2026, extending premium dry-eye pricing.
  • UNITY CS and UNITY M shipped in September 2026, expanding Alcon's installed base.
  • Q2 2026 sales rose 8%, while core EPS grew 11% and cash generation stayed strong.

What critics are saying

  • Alcon discontinued PowerVision IOLs in August 2026 after unpredictable postoperative vision outcomes.
  • Implantables grew only 1% constant currency in Q2 2026, signaling cataract competition.
  • If UNITY adoption slows, Alcon depends on mature cataract tools and Systane cash flow.

What makes Alcon unique

  • Alcon's UNITY surgical platform integrates cataract, vitreoretinal, and microscope workflows across 2026 launches.
  • Systane's preservative-free dry-eye franchise leads global artificial tears and deepens consumer reach.
  • Alcon sells across 140 countries, balancing surgical devices with recurring vision-care consumables.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Medical, dental, & vision coverage
  • HSA Medical Plan
  • PTO
  • Paid Parental leave
  • 401k
  • Retirement Plan Company Contribution
  • Low payroll deductions
  • Tuition Reimbursement Program
  • Annual Bonus
  • Free Family Contact Lens Program
  • 12 Company Paid Holidays

Growth & Insights and Company News

6 month growth

6%

1 year growth

16%

2 year growth

16%
Business Wire
Oct 20th, 2026
Alcon buys Neurotech for $550M to add first FDA-approved MacTel therapy

Alcon has acquired Neurotech Pharmaceuticals for $550 million, adding a rare eye disease therapy to its retina portfolio. The Geneva-based eye care company may owe further contingent payments, including on commercial milestones. Neurotech's ENCELTO is the first and only US Food and Drug Administration (FDA) approved treatment for adults with idiopathic Macular Telangiectasia Type 2 (MacTel). The FDA approved it in March 2025, and it is available only in the US. MacTel is a progressive retinal disease that causes irreversible central vision loss. About 25,000 people in the US have been diagnosed, with 2,000-3,000 new cases each year. Alcon expects the deal to be slightly dilutive to core diluted earnings per share in 2027, and accretive after that.

cash.ch
Oct 20th, 2026
Alcon buys Neurotech for 550 million dollars.

Alcon buys Neurotech for 550 million dollars. Alcon has acquired the US biotech company Neurotech Pharmaceuticals. The ophthalmology specialist is paying 550 million dollars for it and could make further performance-related payments, as stated in a statement on Tuesday. 20.10.2026 13:44 With the acquisition, Alcon is expanding its retina business with Encelto. The drug is the first and only approved treatment in the US for adults with MacTel type 2, a rare retinal disease with progressive loss of central vision. The US drug regulator approved Encelto in March 2025. In the US, according to Alcon, there are around 25,000 diagnosed MacTel patients. Between 2,000 and 3,000 new diagnoses are added each year. Neurotech develops cell therapies for chronic and neurodegenerative eye diseases. The company works with an encapsulated cell therapy intended to release therapeutic proteins in the eye over the long term. Alcon expects the acquisition to slightly increase revenue growth in 2027 and slightly weigh on adjusted earnings per share. Thereafter, the acquisition should be earnings-accretive. awp-robot/rw

Associated Press
Oct 16th, 2026
FDA approves Alcon's Brytly eye drops, lasting up to 50% longer than Lumify

Alcon said the US Food and Drug Administration (FDA) has approved BRYTLY Redness Reliever Eye Drops, a new over-the-counter product for eye redness. The Geneva-based eye care company announced the approval on October 16, 2026. One drop works in a minute and lasts up to 12 hours, Alcon said. Based on label claims, that is up to 50% longer than Lumify, which lasts up to eight hours. BRYTLY contains no bleaches or dyes. Studies showed a low risk of redness rebound when used as directed. "This FDA approval marks an exciting milestone for Alcon," said Jonathan Balch, general manager of Ocular Health & Pharmaceuticals. The drops should reach major US retailers and online stores in the coming months, with other markets to follow.

AD HOC NEWS
Oct 16th, 2026
RxSight announces Alcon lens deal as analysts target RxSight stock at USD 8.17.

RxSight announces Alcon lens deal as analysts target RxSight stock at USD 8.17. Published on 10/16/2026 at 03:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS The October 15, 2026 deal pairs RxSight's adjustable lens technology with Alcon's designs. Twelve firms assign RxSight stock a USD 8.17 consensus target. Collaboration and financial pressure. * RxSight and Alcon agreed on a collaboration worth up to USD 200 million on October 15, 2026. * Second-quarter revenue reached USD 33.7 million, while product sales totaled USD 27.2 million. * Twelve firms assign RxSight a USD 8.17 consensus target. * MarketBeat estimates the next results date as November 4, 2026. * RxSight had a USD 194.2 million market capitalization as of October 15, 2026. RxSight (ISIN US78349D1072) and Alcon announced a non-exclusive collaboration on October 15, 2026, to develop adjustable presbyopia-correcting intraocular lenses with up to USD 200 million in upfront and milestone payments, according to Latham and Watkins. The agreement combines RxSight's post-operative light-adjustable technology with Alcon's optical designs. Discover more Invest in Stocks What does the Alcon deal add? The collaboration gives RxSight a route into presbyopia-correcting lenses while its existing platform remains centered on cataract surgery. The company recognized USD 6.5 million of collaboration revenue in the second quarter of 2026, and its June 30, 2026 balance sheet included USD 208.8 million in cash, cash equivalents and short-term investments, according to RxSight. Why margins still matter. RxSight reported USD 33.7 million of revenue in the second quarter of 2026, including the Alcon contribution, compared with USD 33.6 million in the year-ago quarter. Product sales fell 19 percent year over year to USD 27.2 million, while gross margin excluding collaboration revenue declined to 71.2 percent from 74.9 percent, according to RxSight. The company posted a GAAP net loss of USD 12.1 million, or USD 0.29 per diluted share, for that period. Analyst sentiment remains cautious. MarketBeat reported on October 3, 2026, that twelve firms assigned an average Reduce rating and a USD 8.17 12-month target. The group included three sell ratings, seven hold ratings and two buy ratings. When does RxSight report again? MarketBeat estimates that RxSight will report third-quarter 2026 results on November 4, 2026, after the market closes. The estimate puts the next report at the center of the debate over product demand, collaboration revenue and operating costs. Discover more Stock market analysis NASDAQ stock quotes Eye health blog Stock valuation and next catalyst. RxSight's latest Nasdaq quote was USD 4.67 on October 15, 2026 at 4:00 p.m. ET. The stock had a USD 194.2 million market capitalization and a 52-week range of USD 4.40 to USD 16.74 as of that date. The next reported figures will show whether the Alcon collaboration can offset weaker product sales. RxSight key facts. * Company: RxSight, Inc. * ISIN: US78349D1072 * Ticker: RXST * Primary exchange: Nasdaq * Primary quote: USD 4.67 on October 15, 2026 at 4:00 p.m. ET * Market capitalization: USD 194.2 million (as of October 15, 2026) * 52-week range: USD 4.40-16.74 (as of October 15, 2026) * Sector / Industry: Healthcare / Medical Devices Sponsored Ad Discover more Order Contacts Source Med Gear Find Vision Aids Rxsight stock: new analysis - 21 October. Fresh Rxsight information released. What's the impact for investors? Our latest independent report examines recent figures and market trends. Disclaimer regarding our articles: This is not investment advice, nor is it a recommendation to buy or sell. Information regarding prices, companies, and markets is provided without guarantee; changes may occur at any time. Stock market transactions can result in significant losses. Our articles are created and reviewed, in whole or in part, automatically with the assistance of AI. en | US78349D1072 | RXST | boerse | 70334533 | bgmi

Yahoo Finance
Sep 28th, 2026
Alcon launches Systane PRO PF for 12-hour dry eye relief in Canada

Alcon has launched Systane PRO Preservative-Free in Canada, its longest-lasting dry eye relief formula. The triple-action eye drops provide up to 12 hours of symptom relief for all types of dry eyes. The formula contains hyaluronic acid, HP-guar, nano-sized lipids, and propylene glycol to hydrate, restore, and protect dry eyes. It works by covering the eye surface for instant hydration, providing long-lasting lubrication, and stabilising the tear film to prevent evaporation. Dry eye disease affects an estimated 6 million Canadians and 1.6 billion people globally. Systane is the number one global brand of artificial tears. The new preservative-free formulation addresses symptoms caused by ageing, environmental factors, and digital device use.